TTR and cardiomyopathy: Based on the results of the ATTRibute trial, the FDA approved the clinical use of acoramidis for the treatment of TTR cardiomyopathy (both wildtype and variant) to reduce cardiovascular death and hospitalizations, in late November 2024.